Effects of SlimTrack® Platform on Diet Adherence, Anthropometry and Arterial Stiffness in Postmenopausal Women
NCT ID: NCT06497946
Last Updated: 2024-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
64 participants
INTERVENTIONAL
2024-07-10
2025-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of a Technology-based System and an In-person Behavioral Weight Loss Intervention in the Severely Obese
NCT01537796
Methods Study to Characterize Early Indicators of Weight Loss in People
NCT00383253
Combined Physical-cognitive Exercise and Dietary Intervention for Postmenopausal Obese Women
NCT04768725
Surgical vs. Lifestyle in Obese Older Adults
NCT03137329
Use of Wearable Tech to Increase Physical Activity in Inpatient Rehabilitation for Overweight and Obese Patients
NCT04031079
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A population widely susceptible to weight gain are postmenopausal women. In a physiological context, postmenopause is the last phase of the climacteric period, the reproductive to non-reproductive period, beginning 12 months after the woman's last menstruation, and ending, on average, at 65 years of age. Evidence indicates that 50% of the female population, at this time, has metabolic syndrome, a strong tendency to accumulate visceral abdominal adiposity, seen by an increased abdominal circumference, changes in bone metabolism and greater susceptibility to chronic non-communicable diseases. Among the chronic diseases that develop during menopause are those related to the heart, with high blood pressure, diabetes and coronary disease being the protagonists of this unfavorable scenario, a fact already evidenced by some recent studies that point to women in menopause with a higher prevalence of central arterial stiffness.
Arterial stiffness is the mechanical distension stress induced by anterograde and retrograde systolic waves, which reduces the thickness and fragments elastin fibers, replaced by collagen and protein matrix, with less capacity to dampen pulse wave pressures, increasing the stiffness of the arterial walls and the speed of anterograde and retrograde (or reflex) pulse waves.
Arterial stiffness is assessed using Pulse Wave Velocity (PWV), an important marker of central artery stiffness, considered an early predictor of risk for hypertension and CVD, when PWV \> 10 m/s. For every 1 m/s increase in PWV, there is an increase in the risk of cardiovascular death, cardiovascular events and death from all causes of around 14-15%.
A meta-analysis has already demonstrated that reducing body weight (average of 8% of initial body weight), achieved through diet and lifestyle changes, improved PWV. Both diet and regular exercise have an effect on PWV. reduction in PWV as a consequence of weight reduction, and reducing \>7% of initial body weight has a more robust effect.
Therefore, the management of body weight during menopause, as well as other aspects of women's health, requires a broad spectrum of transdisciplinary action, with dietary and non-dietary interventions as psychological support and encouragement for a more active life. In this context, new technologies represent a comprehensive and accessible alternative for the use of multidisciplinary tools in body weight management, since technological advances have increasingly provided non-invasive methods for health management.
Therefore, the SlimTrack platform presents tools that help both in facing thoughts and emotions that are harmful to long-term weight loss, and with physical activities that promote body self-awareness, meeting the needs of physical activity, and dietary guidelines, contributing to a change in Lifestyle. At this moment, the platform is in the development process through a notice Call CNPq/SEMPI/MCTI nº 021/2021 - RHAE Program - Line 2 - Start-Ups, Process: 424509/2021-0 Creation of an interactive digital platform for the management and treatment of overweight and obesity - Non-Dietary Weight Loss (END), coordinated by Dr. Cláudia Fetter and Dr. Juliana Bertoletti. The first phase or MVP ( minimum viable product ) is made up of 3 stages of 7 days (total 21 days), is in the finalization phase to be made available to the public, scheduled for October 2023. More information about the platform at the link: https://docs.google.com/document/d/1imApA0fw1f5oqDIvegEY0X3yaE3xRxl2UkERZH\_P-yA/edit?usp=sharing
Therefore, in view of the above, as well as the current health scenario and its demands, especially regarding obesity and risk factors associated with health, this project intends to evaluate the effects of the SlimTrack ® Platform on adherence to the diet, variation body weight, anthropometric variables and arterial stiffness in postmenopausal women.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SlimTrack
Use of the SlimTrack Plataform
SlimTrack Plataform
SlimTrack Plataform requests log in and includes anthropometric data of participants, besides answers about questionaires and other tasks in online content available
SlimTrack + Diet Prescription
Use of the SlimTrack Plataform + diet prescription
SlimTrack Plataform
SlimTrack Plataform requests log in and includes anthropometric data of participants, besides answers about questionaires and other tasks in online content available
Diet prescription
Nutrition Professional evaluates diet habits and prescribes a reeducation method in order to fulfill better behavior towards food intake
Diet Prescription
Use of Diet Prescription
Diet prescription
Nutrition Professional evaluates diet habits and prescribes a reeducation method in order to fulfill better behavior towards food intake
Controll
Tips for health with delivery of graphic material
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SlimTrack Plataform
SlimTrack Plataform requests log in and includes anthropometric data of participants, besides answers about questionaires and other tasks in online content available
Diet prescription
Nutrition Professional evaluates diet habits and prescribes a reeducation method in order to fulfill better behavior towards food intake
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Overweight
* Obesity
* Sedentary lifestyle
Exclusion Criteria
* Use of pharmacologial pshychiatric medication
* Recent surgery (six months)
* Recent (six months) cardiardiovascular events (myocardial infarction, stroke)
* Adherence to diet in the last six months
* Attending to psychoterapeutic proccess
45 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto de Cardiologia do Rio Grande do Sul
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Clauda Fetter
Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fernanda Ms Poester, Graduated
Role: STUDY_DIRECTOR
Instituto de Cardiologia RS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto de Cardiologia do Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6092-23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.